“Side versus adverse effects of elexacaftor/tezacaftor/ivacaftor therapy in people with CF”

J.B.A. Gorgels; J. Koopman; E.C. van der Hout; R.W. Hofland; H.G.M. Heijerman; I. Bronsveld

doi:10.1016/j.rmed.2026.108697

February 1, 2026Respiratory MedicineOpen Access

“Side versus adverse effects of elexacaftor/tezacaftor/ivacaftor therapy in people with CF”

View Full Paper

Ask AI

Bookmark

Share

Key Points

This study aims to differentiate between side effects and adverse effects of elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis (CF).
Analyzed real-world efficacy of elexacaftor/tezacaftor/ivacaftor therapy in adults with CF.
Evaluated the nature and duration of side effects and adverse effects of the therapy.
Side effects from CFTR restoration are mostly self-limiting.
Adverse effects due to drug toxicity are more persistent and often lead to therapy discontinuation.

Implication

Clinical evaluation of side versus adverse effects of therapy in adults with cystic fibrosis, highlighting implications for treatment outcomes.

Abstract

ETI demonstrates robust real-world efficacy in adults with CF. Side effects due to CFTR restoration are generally self-limiting, whereas adverse effects from drug toxicity persist longer and are more frequently cause for permanent discontinuation of ETI.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gorgels et al. (2026) studied this question.

synapsesocial.com/papers/698978dff0ec2af6756e71e1 https://doi.org/10.1016/j.rmed.2026.108697

View Full Paper

Ask AI

Bookmark

Share

“Side versus adverse effects of elexacaftor/tezacaftor/ivacaftor therapy in people with CF”

Key Points

Implication

Abstract

Discussion

Cite This Study

“Side versus adverse effects of elexacaftor/tezacaftor/ivacaftor therapy in people with CF”

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading